Clinical Trials Sponsored by Shandong Cancer Hospital and Institute

Total 12682 results

Shandong Cancer Hospital and Institute

Unknown

Intraoperative Molecular Diagnosis of Sentinel Lymph Node In Breast Cancer Patients

Sentinel Lymph Node Biopsy

China
Shandong Cancer Hospital and Institute

Unknown

Consolidation Sintilimab After Concurrent Chemoradiation in Patients With Unresectable Stage III NSCLC (CONSIST)

Carcinoma, Non-Small Cell Lung

China
Shandong Cancer Hospital and Institute

Unknown

Minimally Invasive Biopsy Predicting Breast pCR After NAC for Breast Cancer (MIBPBPCR)

Breast Cancer

China
Shandong Cancer Hospital and Institute

Unknown

The Multi-center Validation Study of Internal Mammary Lymph Biopsy With Modified Injection Technique in Breast Cancer Patients

Breast Neoplasm

China
Shandong Cancer Hospital and Institute

Unknown

Detection of CSF Next Generation Sequencing in the Application of Brain Metastases From Lung Adenocarcinoma or Meningeal Metastasis (CSF)

Recruitment
Shandong Cancer Hospital and Institute

Unknown

Individualized Adaptive Radiotherapy Based on PET/CT and IMRT for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

Lung Neoplasms

China
Shandong Cancer Hospital and Institute

Unknown

Study of Breast Cancer Shrinkage Modes After Neoadjuvant Chemotherapy With Whole-mount Serial Sections and Three-dimensional Pathological and MRI Reconstruction (BCSMANC)

Breast Cancer

China
Shandong Cancer Hospital and Institute
AstraZeneca

Unknown

Open Label, Prospective Study to Investigate Efficacy and Safety of AZD9291 in BM From NSCLC Patients With EGFR T790M

Nonsmall Cell Lung Cancer | Brain Metastases | EGFR-TKI Resistant Mutation | AZD9291
Shandong Cancer Hospital and Institute
BeiGene

Active, not recruiting

A Study of Neoadjuvant Tislelizumab With SBRT in Patients With Resectable Hepatocellular Carcinoma (Notable-HCC)

Hepatocellular Carcinoma

China
Jinming Yu

Recruiting

A Phase Ib Study of TQB2450 Combined With Anlotinib in Patients With Limited Stage Small Cell Lung Cancer After First-line Radiotherapy and Chemotherapy

Limited Stage Small Cell Lung Cancer | Not Progressed After First-line Chemoradiotherapy

China
Zhiyong Yu

Unknown

Potential of Circulating Tumor DNA to Assess the Tumor Response to Neoadjuvant Chemotherapy in Breast Cancer Patients

Breast Cancer | Circulating Tumor DNA | Neoadjuvant Chemotherapy

China
Shandong Cancer Hospital and Institute
Peking University Cancer Hospital & Institute

Unknown

Chemotherapy Combined With Yangzhengxiaoji Capsule in Patients With Advanced Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer
Zhiyong Yu

Not yet recruiting

Pyrotinib and Vinorelbine Tartrate Capsules With or Without Inetetamab for First Line Treatment in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer

Metastatic Breast Cancer
Zhiyong Yu

Not yet recruiting

Capecitabine Versus Vinorelbine in High Risk Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy

Pathologic Residual Cancer Cells

China
Zhiyong Yu

Unknown

Risk and Clinical Benefit of Chemotherapy and Intensive Endocrine Therapy for Luminal B1 Early-stage Breast Cancer

Breast Cancer | Chemotherapy | Endocrine Breast Diseases
Zhiyong Yu

Unknown

Pathological Complete Response Rate in Locally Advanced Breast Cancer With FEC, EC-T, or TC as Neoadjuvant Chemotherapy

Breast Cancer | Neoadjuvant Chemotherapy | Pathological Complete Response
Lei ZHAO

Recruiting

Perioperative Treatment of Resectable Intrahepatic Cholangiocarcinoma With the Combination of Adebrelimab and Apatinib and HAIC

Intrahepatic Cholangiocarcinoma

China
Jinming Yu

Recruiting

Real-World Study of Iruplinalkib in the Treatment of ALK-Positive Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer (NSCLC)

China
Pingping Song

Not yet recruiting

Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer

Non-Small Cell Lung Cancer(NSCLC)

China
Jinming Yu

Recruiting

WX-0593 Combined With Concurrent Chemoradiotherapy in Unresectable Locally Advanced NSCLC

Non-small Cell Lung Cancer (NSCLC)

China
Zhiyong Yu

Not yet recruiting

RWS of Inetetamab HER2 Positive Advanced Breast Cancer

HER2-positive Advanced Breast Cancer
Rongjie Tao

Completed

Apatinib in Recurrent or Refractory Intracranial Central Nervous System Malignant Tumors

Efficacy and Safety

China
Zhiyong Yu

Unknown

The Maintenance Regimen and Revised Regimen for Advanced Breast Cancer Survivors After First-line Salvage Therapy

Breast Cancer | Chemotherapy Effect | Disease-free Survival
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Shandong Cancer Hospital and Institute

Recruiting

IMM2520, a PD-L1 and CD47 Bispecific Antibody in Patients With Advanced Solid Tumors

Breast Cancer | Small Cell Lung Cancer | Colorectal Cancer | Advanced Solid Tumor | Non-small Cell Lung Cancer | Squamous Cell Cancer of Head and Neck

China
Innolake Biopharm
Shandong Cancer Hospital and Institute; Shanghai East Hospital

Recruiting

A Study of ILB2109 in Patients With Advanced Solid Malignancies

Advanced Solid Tumor

China
Shandong Cancer Hospital and Institute
Qilu Hospital of Shandong University; Shandong Provincial Hospital; The Affiliated...

Unknown

Elective Simultaneous Modulated Accelerated Brain Radiation Therapy for NSCLCs With Limited Brain Metastases (SMART-Brain)

Brain Metastases

China
Shandong Cancer Hospital and Institute
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Trial of Conversion Treatment of HAIC Combined With Camrelizumab and Apatinib for Unresected Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Jinming Yu
Roche Pharma AG

Unknown

Phase II Study of Erlotinib With Concurrent Radiotherapy in Unresectable NSCLC With Activating Mutation of EGFR in Exon 19 or 21 (RECEL)

Non-small Cell Lung Cancer

China
Shandong Cancer Hospital and Institute
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Neoadjuvant Study of Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer (TNBC)

Triple Negative Breast Cancer

China
Shandong Cancer Hospital and Institute
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Hypofraction Radiotherapy in Patients With NSCLC

Non-Small-Cell Lung Cancer

China
Shandong Cancer Hospital and Institute
Henan Cancer Hospital; The Affiliated Hospital of Qingdao University

Unknown

Internal Mammary Sentinel Lymph Node Biopsy With Modified Injection Technique

Breast Cancer

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Tianjin Medical University Cancer Institute and Hospital; Shandong Cancer Hospital...

Recruiting

TAA06 Injection in the Treatment of Patients With B7-H3-positive Relapsed/ Refractory Neuroblastoma

B7-H3-positive Relapsed/ Refractory Neuroblastoma

China
The Second Hospital of Shandong University
Shandong Cancer Hospital and Institute; Wuhan YZY Medical Science and Technology...

Unknown

Detection of Circulating Tumor Tells as The Guidance of the Neoadjuvant Chemotherapy of Esophageal Cancer

Esophageal Cancer TNM Staging Primary Tumor (T) T3

China
Shandong Cancer Hospital and Institute
The First Affiliated Hospital of Nanchang University

Recruiting

A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With Double Expression Diffuse Large B-cell Lymphoma

The First Affiliated Hospital of Nanchang University

China
Shandong University
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Withdrawn

Alteration of Different Immune Parameters in Immune Thrombocytopenia （ITP） Patients Receiving Eltrombopag Treatment

Immune Thrombocytopenia

China
Peking University People's Hospital
Peking University Shougang Hospital; Shandong Cancer Hospital and Institute

Recruiting

Weekly Irinotecan Liposomes in Recurrent or Refractory Ewing Sarcoma

Ewing Sarcoma

China
Shandong University
Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Shandong... and other collaborators

Unknown

Decitabine Combining Dexamethasone Versus Dexamethasone in Management of ITP

Purpura, Thrombocytopenic, Idiopathic | Immune Thrombocytopenia

China
Yongsheng Wang
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Select the Appropriate Population for Adding CDK4/6i to Neoadjuvant Endocrine Therapy

Locally Advanced Breast Cancer | Hormone Receptor Positive，HER2-negative Breast Cancer

China
Shandong Cancer Hospital and Institute
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Trial of Anlotinib Combined With Docetaxel in Patients With Wild-type Advanced Non-squamous Non Small Cell Lung Cancer

Non Small Cell Lung Cancer

China
Shandong Cancer Hospital and Institute
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Trial of Anlotinib Combined With Docetaxel in EGFR Mutations Advanced Non Small Cell Lung Cancer Patients

Non Small Cell Lung Cancer

China
Jinming Yu
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer (INPHASE)

Metastatic Breast Cancer | HER2-positive Breast Cancer

China
Rongjie Tao
National Natural Science Foundation of China

Unknown

High-dose Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases

Brain Metastases

China
Rongjie Tao
National Natural Science Foundation of China

Unknown

Temozolomide, Nedaplatin, Vincristine, and Radiotherapy as First-line Treatment in Newly Diagnosed Primary CNS Lymphoma

Central Nervous System Tumors

China
Wei Zhao
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Unknown

Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease

Hematological Neoplasms

China
Rongjie Tao
National Natural Science Foundation of China

Unknown

Pemetrexed and Temozolomide in Treating Patients With Relapsed Primary Central Nervous System Lymphoma （PCNSL）

Central Nervous System Tumors
Zhejiang Cancer Hospital
Fudan University; Cancer Institute and Hospital, Chinese Academy of Medical... and other collaborators

Completed

Recombinant Human Endostatin Continued Pumping Into Vein Combining With CCRT in Unresectable Stage III NSCLC

Stage III Non-small-Cell Lung Cancer

China
Shandong Cancer Hospital and Institute
Cancer Institute and Hospital, Chinese Academy of Medical Sciences; RenJi Hospital and other collaborators

Completed

Erbitux Combined With Chemo-radiotherapy in Esophageal Squamous Cell Carcinoma (EXCEL)

Esophageal Cancer

China
Shandong University of Traditional Chinese Medicine
Shandong Institute of Science and Technology Information

Not yet recruiting

Shenfu Injection for Postoperative Delirium (SFI for POD) (POD)

Postoperative Delirium
Beijing Chao Yang Hospital
Wuhan University; Shandong Provincial Hospital; Shandong Cancer Hospital and... and other collaborators

Unknown

Safety and Efficacy Study of Cylindrical Abdominoperineal Resection to Treat Rectal Cancer

Postoperative Complications | Rectal Cancer | Treatment | Neoplasm Recurrence, Local | Survival Rate

China
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Peking University Cancer Hospital & Institute

Unknown

PEG-rhG-CSF in Elderly Patients With Small Cell Lung Cancer Receiving Chemotherapy

Small Cell Lung Cancer | PEG-rhG-CSF

China

Clinical Trials Sponsored by Shandong Cancer Hospital and Institute

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Azerbaijan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations